MannKind Corporation announced that it has begun clinical development of a next-generation inhalation system to optimize the delivery of drug powders based on the proprietary Technosphere technology platform. The inhalation system is as small as a whistle and designed to be easy-to-use, discreet and patient-friendly when used with therapies such as the investigational ultra rapid acting insulin AFRESA (insulin human [rDNA origin]) Inhalation Powder. The delivery system technology can also be used with other therapeutic proteins.
“The development of this new, compact inhalation delivery system is further evidence of MannKind’s commitment to invest in the kind of technical innovation that will meet patient needs in a number of therapeutic areas,” said Hakan S. Edstrom, President and Chief Operating Officer of MannKind Corporation. “Our goals with this technology platform are to enhance drug delivery and performance, improve simplicity of use for patients and service the expanding market of patient self-administration.”
MannKind’s proprietary Technosphere technology platform is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The technology enables rapid systemic delivery of a broad range of therapeutic agents, including proteins, peptides and small molecule drugs, via oral inhalation to the deep lung utilizing MannKind’s proprietary delivery systems.